SK Bioscience Q2 Sales Reach KRW 161.9 Billion

Sales Grow Sixfold Year-on-Year

SK Bioscience announced on the 31st that its consolidated sales for the second quarter of 2025 reached KRW 161.9 billion, marking a 504.5% increase compared to the same period last year. However, operating losses increased to KRW 37.4 billion, and net losses also expanded to KRW 16.8 billion.

The increase in sales appears to be driven by the inclusion of IDT Biologika, a subsidiary acquired last year, as well as strong sales of SK Bioscience's proprietary vaccines. IDT Biologika, which was incorporated last year, continued its stable growth by increasing sales in the second quarter following the first quarter, thanks to improved productivity and additional order intake.

IDT Biologika, which has achieved over KRW 100 billion in sales for three consecutive quarters since being acquired by SK Bioscience, plans to continue improving its performance in the second half of the year by focusing on expanding CDMO orders centered on European and North American clients and securing new partners.

However, despite the increase in sales, operating losses continued due to ongoing clinical trials for major pipelines, research and development (R&D), and facility investments.